Global Top Players in Intraocular Lens (IOL) Market

Ophthalmology

Ocular Therapeutix’s insert fails in phase 2; C...

Ocular Therapeutix’s dry eye disease insert fails in phase 2 trial Ocular Therapeutix declared that its OTX-CSI (cyclosporine intracanalicular insert) for dry eye disease (DED) has flunked to reach...

Oct 26, 2021

von-willebrand-disease-vwd-market
von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improperly. Blood contains numerous proteins that aid in blood clotting when necessary. Von Willebrand factor is one of these proteins (VWF). VWD patients have either a low level of VWF in their blood or the VWF protein does not functi...

Find More
medtech-news-updtes-updates-for-syntellix-bausch-lomb-movair-cochlear-laborie
Bausch + Lomb’s LuxSmart Intraocular Lenses; Movair’s Luisa Life Supporting Ventilator; Cochlear’s Nucleus and Baha Systems; Laborie Acquires Pelvalon; Know Labs’s SARS-CoV-2 Research; Syntellix’s MAGNEZIX;

Syntellix obtains product approval for India On October 07, 2021, Syntellix obtained the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market from India's Central Drugs Standard Control Organisation (CDSCO) for the Indian market. With this approva...

Find More
pharma-biotech-news-updates-for-biogen-smartlabs-synlogic-partner-therapeutics
Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain

Win-win for Biogen as its Biosimilar Gets Approval for AMD  Samsung Bioepis and Biogen's biosimilar drug, Byooviz, received USFDA approval for the treatment of vision loss, Age-related macular degeneration and has become the first biosimilar to Lucentis in the AMD market. The Lucentis copycat had also manag...

Find More

More Views & Analysis

pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics
FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A f...

Find More

duchenne-muscular-dystrophy-market-size-share-trends-companies-cagr-growth-therapy-treatment-therapeutics
Duchenne Muscular Dystrophy Market: What’s More Beyond Exon-Skipping Therapies?

Duchenne muscular dystrophy (DMD) is a rare genetic disorder usually diagnosed in young boys, gradually weakening muscles across the body until the heart or lungs fail. Symptoms often show up by the age of 5; as the disease progresses, patients tend to lose the ability to walk around the age of 12. As per a re...

Find More

advances-in-diabetes-care-treatment-devices-management-approaches
New Approaches and Evolutions to Reshape the Diabetes Management and Care

As per the WHO, “the number of people affected with Diabetes has grown significantly from 108 million in 1980 to 422 million in 2014. A rising trend in prevalence is observed in low- and middle-income countries as compared to high-income countries”. Additionally, Diabetes is a significant cause of the number of dea...

Find More

pharma-news-and-updates-for-nanox-takeda-visus-lqt-therapeutics
LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.  The two-year-old Canadian biotech will utiliz...

Find More

medtech-news-updates-for-nevro-nuvasive-medtronic-boston-angelmed-memed
Nevro’s Spinal Cord Stimulation; Boston’s PINNACLE FLX; NuVasive’s Modulus ALIF; J&J’s VERITAS Vision System; Medtronic’s DCB Catheter; AngelMed’s Heart Attack Warning System

Nevro Received FDA Approval of its 10 kHz High-Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy On July 19, 2021, Nevro Corp. received approval for its Senza System, Nevro's unique 10 kHz stimulation, to treat chronic pain associated with Painful...

Find More

Latest-pharma-happenings-for-rallybio-sanofi-eureka-lilly-unity-biotechnology
Unity’s advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka’s candidate; Lilly invests in MiNA;

UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Advanced Vascular Eye Disease patients  UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to decrease, impede, or reverse diseases of aging, declared positive data from its Phase 1 safety study of U...

Find More

T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....

Find More

Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by musc.....

Find More

Real-world evidence (RWE) is used in an exponential way to guide payment decisions and access system.....

Find More

Well, MDS being one of the rare blood cancers, has been into the limelight of researchers since a de.....

Find More

Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder o.....

Find More

There are about 200 different types of cancer, making it one of the most diverse types of indication.....

Find More